Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023
18 January 2023 - 3:29AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the
“Company”), a biotechnology company developing novel therapeutic
candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death for drug resistant
and devastating cancers, will present at the Virtual Sidoti
Micro-Cap Conference being held on January 18-19, 2023.
Mr. Randy Milby, Founder and Chief Executive Officer of
Hillstream BioPharma, is scheduled to present on Thursday, January
19, 2023 at 10:00 a.m. EST and will also be available for 1-on-1
meetings with the investment community.
To register for the conference, access the livestream, and
request to participate in 1-on-1 meetings with Mr. Milby, please
access this link:
https://sidoti.zoom.us/webinar/register/WN_AGPD5ts5STqZfzhlcoUVrQ
To view the archived recordings for the presentation, please
visit the Hillstream BioPharma website at:
ir.hillstreambio.com.
About Hillstream BioPharma, Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing novel
therapeutic candidates against drug-resistant and devastating
cancers. Hillstream’s most advanced candidate, HSB-1216, expected
to enter clinical trials in 2023, targets ferroptosis, an emerging
new anti-cancer mechanism resulting in iron mediated cell death for
drug resistant and devastating cancers. Hillstream’s most advanced
candidate is HSB-1216, an IMCD modulator, whose active drug was
found to be efficacious in a clinical pilot study in Germany in
drug resistant tumors, including triple negative breast cancer and
epithelial carcinomas. Hillstream intends to initiate IND
discussions with the FDA in first half of 2023. Hillstream uses
Quatramer™, a proprietary tumor targeting platform which extends
duration of action and minimizes off-target toxicity, with HSB-1216
as well as biologics, mRNA, peptides and other modalities in the
tumor microenvironment. Quatrabody™ conjugates immuno-oncology
targets with greater binding affinity than approved therapies.
Hillstream Quatramers with novel biologics developed against
proprietary undruggable epitopes of PD-1 and other validated will
enter the rapidly growing immuno-oncology therapeutics market
leading with HSB-1940, targeting PD-1, followed by additional
targets including PD-L1, HER-2 and TROP-2. For more
information, please visit: www.hillstreambio.com.
Investor Relations
Contact:investorrelations@hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2024 to May 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From May 2023 to May 2024